quinone has been researched along with Parkinson Disease in 9 studies
benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups.
1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene.
quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Parkinson's disease is a neurodegenerative disorder associated with progressive loss of dopaminergic cells in the substantia nigra." | 1.33 | Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. ( Cho, Y; Choi, HJ; Hwang, O; Lee, SY, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Lü, MH | 1 |
| Wang, ZP | 1 |
| Xing, LZ | 1 |
| Zhang, W | 1 |
| Han, F | 1 |
| Huang, GL | 1 |
| Liu, W | 1 |
| Zhang, YX | 1 |
| Xu, J | 1 |
| Cui, J | 1 |
| Bagh, MB | 2 |
| Maiti, AK | 2 |
| Jana, S | 2 |
| Banerjee, K | 2 |
| Roy, A | 2 |
| Chakrabarti, S | 2 |
| Rekas, A | 1 |
| Knott, RB | 1 |
| Sokolova, A | 1 |
| Barnham, KJ | 1 |
| Perez, KA | 1 |
| Masters, CL | 1 |
| Drew, SC | 1 |
| Cappai, R | 1 |
| Curtain, CC | 1 |
| Pham, CL | 1 |
| Anderson, DG | 1 |
| Mariappan, SV | 1 |
| Buettner, GR | 1 |
| Doorn, JA | 1 |
| Zahid, M | 1 |
| Saeed, M | 1 |
| Yang, L | 1 |
| Beseler, C | 1 |
| Rogan, E | 1 |
| Cavalieri, EL | 1 |
| Asanuma, M | 2 |
| Miyazaki, I | 2 |
| Diaz-Corrales, FJ | 2 |
| Ogawa, N | 2 |
| Choi, HJ | 1 |
| Lee, SY | 1 |
| Cho, Y | 1 |
| Hwang, O | 1 |
| Das, A | 1 |
| Shimizu, M | 1 |
| Tanaka, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Placebo Controlled Trial of Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke[NCT04918719] | Phase 2 | 118 participants (Anticipated) | Interventional | 2021-06-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for quinone and Parkinson Disease
| Article | Year |
|---|---|
Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism.
Topics: Animals; Benzoquinones; Dopamine; Humans; Neurons; Neurotoxins; Oxidative Stress; Parkinson Disease; | 2004 |
8 other studies available for quinone and Parkinson Disease
| Article | Year |
|---|---|
Hybrids of polyphenolic/quinone acids, the potential preventive and therapeutic drugs for PD: Disaggregate α-Syn fibrils, inhibit inclusions, and repair damaged neurons in mice.
Topics: alpha-Synuclein; Animals; Benzoquinones; Horses; Lewy Bodies; Mice; Neurons; Parkinson Disease | 2023 |
Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's disease.
Topics: Acetylcysteine; Adenosine Triphosphate; Animals; Benzoquinones; Brain; Disease Models, Animal; Dopam | 2008 |
The structure of dopamine induced alpha-synuclein oligomers.
Topics: alpha-Synuclein; Amyloid; Benzoquinones; Circular Dichroism; Cross-Linking Reagents; Dopamine; Elect | 2010 |
Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone.
Topics: 3,4-Dihydroxyphenylacetic Acid; Benzoquinones; Cyclooxygenase 2; Free Radicals; Humans; Oxidation-Re | 2011 |
Formation of dopamine quinone-DNA adducts and their potential role in the etiology of Parkinson's disease.
Topics: Acetylcysteine; Antioxidants; Benzoquinones; DNA Adducts; Dopamine; Humans; Hydrogen-Ion Concentrati | 2011 |
Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Benzoquinones; Biopterins; Cell Death; Cell | 2005 |
Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzoquinones; Brain; Dopamine; Electron Transport; Electro | 2007 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; | 2005 |